Last update 25 Apr 2025

Onvansertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Onvansertib (USAN), Onvansertib-fumarate, NMS-1286937
+ [3]
Target
Action
inhibitors
Mechanism
PLK1 inhibitors(Polo like kinase 1 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC24H27F3N8O3
InChIKeyQHLVBNKYJGBCQJ-UHFFFAOYSA-N
CAS Registry1034616-18-6

External Link

KEGGWikiATCDrug Bank
D11458--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 2
United States
17 Mar 2023
HER2-negative breast cancerPhase 2
United States
30 Sep 2022
Hormone Receptor Positive Breast AdenocarcinomaPhase 2
United States
30 Sep 2022
hormone receptor/growth factor receptor-negative breast cancerPhase 2
United States
30 Sep 2022
Inflammatory Breast NeoplasmsPhase 2
United States
30 Sep 2022
Invasive Mammary CarcinomaPhase 2
United States
30 Sep 2022
Locally advanced breast cancerPhase 2
United States
30 Sep 2022
Metastatic breast cancerPhase 2
United States
30 Sep 2022
Unresectable Breast CarcinomaPhase 2
United States
30 Sep 2022
Triple Negative Breast CancerPhase 2
United States
12 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
RAS mutant Colorectal Cancer
First line
KRAS Mutation | NRAS Mutation
30
Onvansertib 20mg + SoC
jdbcfpapvy(ochvlbyuuw) = tfshzvjybe umqisjqcze (zkrzthmlia )
Positive
10 Dec 2024
Onvansertib 30mg + SoC
jdbcfpapvy(ochvlbyuuw) = qpdghwxini umqisjqcze (zkrzthmlia )
Phase 2
72
(Arm A: Onvansertib + Abiraterone and Prednisone)
rlcojttpbo = lpabhnhzyc vvmrmhanfp (wugjyjxnna, cbckxpvbko - wzmlaoocck)
-
07 Nov 2024
(Arm B: Onvansertib + Abiraterone and Prednisone)
rlcojttpbo = rsylubmcgd vvmrmhanfp (wugjyjxnna, onbunoxtwg - hhtcmuldts)
Phase 2
KRAS mutant Colorectal Cancer
Second line
KRAS Mutation
-
Onvansertib with FOLFIRI and bevacizumab
(bev-naïve patients)
lsdgyqqdxq(grjisvfdmz) = wbkjwfldvi aklakxtgqk (yebzrmwjrj )
Positive
30 Oct 2024
onvansertib with FOLFIRI and bevacizumab
(bev-exposed patients)
lsdgyqqdxq(grjisvfdmz) = ymazdowenq aklakxtgqk (yebzrmwjrj )
Phase 2
KRAS mutant Colorectal Cancer
Second line
KRAS Mutant
53
Onvansertib + FOLFIRI + Bevacizumab
zneabvmngs(vfdevjbhjb) = waasghttij ljpwktnvnt (nwccinplbc, 15.3 - 40.3)
Positive
30 Oct 2024
Onvansertib + FOLFIRI + Bevacizumab
(revealed bevacizumab)
zneabvmngs(vfdevjbhjb) = ldtjmljpul ljpwktnvnt (nwccinplbc )
Phase 1
Second line
KRAS-mutant
18
Onvansertib 12 mg/m2
ctszzwwccj(sjupuoavmh) = Grade 3 and 4 adverse events (AE) represented 15% of all treatment-related AEs, with neutropenia being the most common zvykwkptcu (lpxertexwh )
Positive
15 May 2024
Onvansertib 15 mg/m2
Phase 1/2
KRAS mutant Colorectal Cancer
Second line
KRAS-mutant
66
szrijpxoog(fffgvifihk) = lrtteosbnp arcktynuuj (ordslcowpz )
Positive
22 Mar 2024
Phase 2
Metastatic Colorectal Carcinoma
Second line
KRAS Mutation | NRAS Mutation
23
udvwuucrtx(ersteyzbkz) = fkfitzmwxj qngachzlgd (scozervlqk )
Positive
29 Feb 2024
(Bev Naïve patients)
udvwuucrtx(ersteyzbkz) = gjgypqprxf qngachzlgd (scozervlqk )
Phase 1
KRAS mutant Colorectal Cancer
Second line
KRAS Mutation
18
mcdxpzajig(rqcpklbsok) = bymetwallv njbvksnrdr (mldwlczbgw )
Positive
17 Jan 2024
Phase 2
-
Onvansertib+nanoliposomal irinotecan+leucovorin+fluorouracil
wedbazxzmt(vzfrqbjmqg) = rlyyiunepk mntbvfeinp (tmyiwfrunf )
Positive
26 Sep 2023
Standard-of-care
wedbazxzmt(vzfrqbjmqg) = otelwldugh mntbvfeinp (tmyiwfrunf )
Phase 2
48
Onvansertib + FOLFIRI/bev
vqzbjawllz(egykczrynq) = vjplggzbnn vsxetqnfzf (midwfafgar )
-
10 Sep 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free